Kazia Therapeutics (NASDAQ:KZIA) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday.
The Kazia Therapeutics clinical trial covered the company’s paxalisib as a treatment of glioblastoma. Results from the trial came out positive when compared to the standard of care (SOC).
The big news was the increase in the median Overall Survival (OS) period to 14.77 months. For the record, the SOC median OS rate is 13.84 months. A secondary analysis also showed a median OS of 15.54 months.
Tha news triggered a rally for KZIA stock that saw its shares undergo a major gains. That came alongside heavy trading as investors bought up the company’s shares.
KZIA Stock Movement Today
The rally for KZIA stock isn’t over yet with the company’s shares up another 51.3% as of Thursday afternoon. That has the stock up 123.3% since the start of the year.
Kazia Therapeutics also continues to see heavy trading on Thursday with more than 182 million shares on the move. This is a major increase when compared to its daily average trading volume of about 7.5 million shares.
Investors on the lookout for even more of the latest stock market stories today are going to want to stick around!
We have all of the hottest stock market news that traders need to know about on Thursday! A few examples include what’s happening with shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) stock, Broadcom (NASDAQ:AVGO) stock and QuantumScape (NYSE:QS) stock. You can read up on all of that at the following links!
More Thursday Stock Market News
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
